Amarantus Enters Into CRO Agreement With Chiltern International to Commence Phase 2b Clinical Development of Eltoprazine in Parkinson's Disease Levodopa-Induced Dyskinesia
I wouldn't call it a squeeze by any stretch, although I think it could happen one day with onvo. I know a tout service recently - a week ago? - published these comments for their subscribers. looks a whole lot like onvo;
• This disruptive biotech has successfully discovered a way to grow human organs from scratch.
• It has exclusive rights to deliver treatment for the next seven to 10 years.
• It’s the ONLY company with access to a $770-million-market opportunity.
As you can see, “luck” is about as far removed as possible…
The stock I’m talking about trades for under $5. One simple investment now could set you up for years.
google; L'Oreal's plan to start 3d printing human skin
today; announced that it has completed a study of mesencephalic-astrocyte-derived neurotrophic factor (MANF) administration to the putamen and the substantia nigra of pigs by convection-enhanced delivery. This study generated MANF brain delivery and distribution data, further supporting the rationale for MANF's development in the treatment of Parkinson's disease (PD). The study was conducted in the United Kingdom in collaboration with Renishaw plc's (LON:RSW) Neurological Applications Department and its leading academic partner, Functional Neurosurgery Research Group at the University of Bristol.
ron, respect your concerns but the end-game is stem cells. that trial will be approved. those are the results that matter at this point.
Amarantus Receives Notice of Allowance for U.S. Patent Application Covering Proprietary Methods of Administration and Compositions in the Treatment of Parkinson's Disease . . .Notice of Allowance was received from the U.S. Patent and Trademark Office (USPTO) for U.S. Patent Application Serial No. 11/713,156 entitled, "Pharmacological Treatment of Parkinson's Disease." Upon issuance, the patent will provide additional intellectual property protection for the Company's lead product candidate, eltoprazine.
until you really know what you're doing, put a nice chunk of your money in PRHSX - look it up. the rest of your money is just spending the weekend in vegas. good luck! oh, and . . . no one owns enough nviv
commercial after commercial . . . . we'll be right back . . . . . some broken newshead banter . . . commercial after commercial . . . . etc . . . etc . . . intolerable
that is so funny - I don't think there are many around that remember kingatml, one of the most annoying bashers ever - all day every day . . . no more fnkenny, copperheadangie, alpodell, . . .
pleeeease stop engaging